SkinPlus-HYAL

BioPlus is a South Korean biotechnology company specializing in the development and manufacturing of advanced hyaluronic acid (HA) fillers and biomedical products. The company is best known for its proprietary MDM technology, which produces high-viscosity, long-lasting fillers like the SkinPlus-HYAL line. Beyond aesthetics, BioPlus is expanding its portfolio into anti-adhesion agents, synovial fluid replacements, and long-acting bio-therapeutics, including GLP-1 analogues for diabetes and obesity. The company operates GMP-certified facilities and maintains a strong global presence through exports to over 60 countries. BioPlus is publicly traded on the KOSDAQ exchange and continues to invest in R&D for next-generation biologics.